Javed Butler, MD, MPH, MBA

Drs James Januzzi, Javed Butler, Robert Mentz, and Muthiah Vaduganathan share practice pearls for treating patients with heart failure, focusing on the future of treatment.

Robert Mentz, MD, reviews the results of the STONG-HF trial for patients in the hospital for heart failure.

Experts in cardiology comment on the impact of recent trials on heart failure with preserved ejection fraction (HFpEF) in clinical practice.

Muthiah Vaduganathan, MD, MPH, provides an overview of the pooled data from the PARAGLIDE-HF and PARAGON-HF clinical trials in heart failure.

Experts in cardiology discuss the use of sacubitril/valsartan in patients with heart failure with preserved ejection fraction (HFpEF), highlighting the PARAGLIDE-HF study.

Robert J. Mentz, MD, and Javed Butler, MD, MPH, MBA, comment on the use of beta blockers and other agents in patients with heart failure preserved ejection fraction (HFpEF).

Robert J. Mentz, MD, reviews the current unmet needs for patients with heart failure, highlighting triple or quadruple therapy.

Javed Butler, MD, MPH, MBA, comments on implementing, continuing or cutting back on quadruple therapy after patient’s cardiac function has improved.

Drs James Januzzi, Javed Butler, Robert J. Mentz, and Muthiah Vaduganathan share approaches to sequencing quadruple therapy in heart failure to the individual patient, as well as optimizing therapy early in the hospitalization stage.

Javed Butler, MD, MPH, MBA, discussesSGLT-2 inhibitors and their use in heart failure.

Experts in cardiology highlight the four pillars of guideline directed therapies in heart failure.

Robert J. Mentz, MD, and James Januzzi, MD, discuss the key takeaways from updated heart failure guidelines, highlighting heart failure stages A and B.

Muthiah Vaduganathan, MD, MPH, and Javed Butler, MD, MPH, MBA, share approaches to treating patients with heart failure, focusing on patient education as well as social determinants of health.

Experts in cardiology review the classification of heart failure using left ventricle ejection fraction (EF).

Muthiah Vaduganathan, MD, MPH, comments on the impact of recurrent rehospitalizations for heart failure on survival.

Javed Butler, MD, MPH, MBA, and Robert J. Mentz, MD, review the current prevalence of heart failure in the US and Europe, as well as the clinical and economic challenges that arise with increasing prevalence.

Expert cardiologists share strategies for educating patients on the treatment and management of hypertrophic cardiomyopathy.

Drs Steve R. Ommen, Martin S. Maron, Javed Butler, and James Januzzi provide insight on the evolving treatment landscape for obstructive hypertrophic cardiomyopathy.

A panel of experts in cardiovascular medicine review the use of mavacamten as seen in the VALOR-HCM study for patients with symptomatic oHCM who are eligible for septal reduction therapy.

Martin S. Maron, MD, examines long-term data with mavacamten for oHCM treatment that was presented at ACC 2022.

Cardiac specialists discuss improvement in health status with different treatments for hypertrophic cardiomyopathy.

John A. Spertus, MD, MPH, and Martin S. Maron, MD comment on the role of mavacamten in oHCM as seen in the EXPLORER-HCM trial.

Steve R. Ommen, MD, discusses the use of novel agents in the pipeline for the treatment of obstructive hypertrophic cardiomyopathy (oHCM).

Steve R. Ommen, MD, leads a discussion on factors to consider when choosing treatment for hypertrophic cardiomyopathy (HCM).

Experts in cardiology review invasive treatments, challenges with HCM treatments, and how to optimize treatment for patients.

Drs Javed Butler, Martin S. Maron, Steve R. Ommen, and James Januzzi provide insight on approaching treatment of HCM with pharmacologic and nonpharmacologic interventions.

Steve R. Ommen, MD; and Martin S. Maron, MD, review the role of AHA/ACC guidelines, imaging techniques, and circulating biomarkers in approaching the diagnosis and treatment of hypertrophic cardiomyopathy.

John A. Spertus, MD, MPH, comments on the effect of oHCM on health status and quality of life for patients.

Drs Steve R. Ommen, Martin S. Maron, John A. Spertus, Javed Butler, and James Januzzi provide insight on the presentation of nonobstructive and obstructive hypertrophic cardiomyopathy.

Steve R. Ommen, MD, leads a review of common mutations seen in hypertrophic cardiomyopathy and the role of biomarkers and genetic testing in HCM.